JP2023550094A5 - - Google Patents

Info

Publication number
JP2023550094A5
JP2023550094A5 JP2023529970A JP2023529970A JP2023550094A5 JP 2023550094 A5 JP2023550094 A5 JP 2023550094A5 JP 2023529970 A JP2023529970 A JP 2023529970A JP 2023529970 A JP2023529970 A JP 2023529970A JP 2023550094 A5 JP2023550094 A5 JP 2023550094A5
Authority
JP
Japan
Prior art keywords
hla
peptide
optionally
mhc
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023529970A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023550094A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/059050 external-priority patent/WO2022104002A2/en
Publication of JP2023550094A publication Critical patent/JP2023550094A/ja
Publication of JP2023550094A5 publication Critical patent/JP2023550094A5/ja
Pending legal-status Critical Current

Links

JP2023529970A 2020-11-12 2021-11-12 Ｓａｒｓ－ｃｏｖ－２免疫優性ペプチドの構築物及びその使用 Pending JP2023550094A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063113024P 2020-11-12 2020-11-12
US63/113,024 2020-11-12
PCT/US2021/059050 WO2022104002A2 (en) 2020-11-12 2021-11-12 Sars-cov-2 immunodominant peptide constructs and uses thereof

Publications (2)

Publication Number Publication Date
JP2023550094A JP2023550094A (ja) 2023-11-30
JP2023550094A5 true JP2023550094A5 (enExample) 2025-07-22

Family

ID=80777877

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023529970A Pending JP2023550094A (ja) 2020-11-12 2021-11-12 Ｓａｒｓ－ｃｏｖ－２免疫優性ペプチドの構築物及びその使用

Country Status (4)

Country Link
US (1) US20230398205A1 (enExample)
EP (1) EP4244630A4 (enExample)
JP (1) JP2023550094A (enExample)
AU (3) AU2021323389B1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115785231A (zh) * 2021-09-10 2023-03-14 广东菲鹏生物有限公司 一种鉴别新冠突变型抗原的抗体、试剂及方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2500955A1 (en) * 2002-10-03 2004-04-15 Genencor International, Inc. Optimized multi-epitope constructs and uses thereof
ES2529736T3 (es) * 2003-04-10 2015-02-25 Novartis Vaccines And Diagnostics, Inc. Composición inmunogénica que comprende una proteína espicular del coronavirus del SARS
WO2004110349A2 (en) * 2003-05-14 2004-12-23 Siga Technologies, Inc. Sars t cell epitopes and methods for identifying same
JP2022532922A (ja) * 2019-05-21 2022-07-20 エスペロバックス インコーポレイティド 酵母ベースの経口ワクチン接種
BR112022001185A2 (pt) * 2019-08-01 2022-03-15 Acm Biolabs Pte Ltd Método de eliciamento de uma resposta imune administrando uma população de polimerossomos tendo um antígeno associado com uma população de polimerossomos tendo um adjuvante associado, bem como composições compreendendo as duas populações de polimerossomos
TW202200199A (zh) * 2020-03-20 2022-01-01 美商百歐恩泰美國公司 冠狀病毒疫苗及使用方法
KR20250107297A (ko) * 2020-04-02 2025-07-11 리제너론 파아마슈티컬스, 인크. 항-sars-cov-2 스파이크 당단백질 항체 및 항원-결합 단편
IL297419B2 (en) * 2020-04-22 2025-02-01 BioNTech SE Coronavirus vaccine
JP2023525518A (ja) * 2020-05-06 2023-06-16 モレキュラー パートナーズ アクチェンゲゼルシャフト 新規アンキリンリピート結合タンパク質とその用途
KR20230025670A (ko) * 2020-05-19 2023-02-22 그릿스톤 바이오, 인코포레이티드 Sars-cov-2 백신
CN111647054B (zh) * 2020-06-12 2021-12-03 上海祥耀生物科技有限责任公司 一种用于检测新型冠状病毒SARS-CoV-2抗体的试剂及其应用
US20230241205A1 (en) * 2020-06-17 2023-08-03 Tscan Therapeutics, Inc. Sars-cov-2 immunodominant peptides and uses thereof
WO2022049595A1 (en) * 2020-09-01 2022-03-10 Helmholtz Zentrum für Infektionsforschung GmbH Multi-patch vaccines and immunogenic compositions, methods of production and uses thereof

Similar Documents

Publication Publication Date Title
US20210017599A1 (en) Cancer antigen-specific t-cell receptor gene, peptide encoded by the gene, and use of them
JP6192537B2 (ja) Ｔ細胞の標的抗原の同定
Romero et al. Novel methods to monitor antigen-specific cytotoxic T-cell responses in cancer immunotherapy
US20050130117A1 (en) Modulators of lymphocyte activation and migration
JP6718450B2 (ja) キメラ抗原受容体及びその使用方法
US7678379B2 (en) Mycobacterium tuberculosis epitopes and methods of use thereof
JP2024546018A5 (enExample)
US7521192B2 (en) EDG: modulators of lymphocyte activation and migration
JP2007536522A (ja) Ｃｔｌの媒介による抗原提示細胞の溶解を検出するためのｍｈｃ架橋系
Hill et al. Early‐onset myasthenia gravis: A recurring T‐cell epitope in the adult‐specific acetylcholine receptor ε subunit presented by the susceptibility allele HLA‐DR52a
JP2024515646A5 (enExample)
AR124054A1 (es) CONSTRUCCIONES DE PÉPTIDOS INMUNODOMINANTES DE SARS-CoV-2 Y SUS USOS
JP2023550094A5 (enExample)
JP5999703B2 (ja) ＨＬＡ−ＤＲ１拘束性Ｔａｘ特異的ＣＤ４＋Ｔ細胞エピトープ
Asano et al. Tumor regression following engineered polyomavirus-specific T cell therapy in immune checkpoint inhibitor-refractory merkel cell carcinoma
EP4378533A1 (en) Patient selection and therapy monitoring for autoimmune disorders
US20130189282A1 (en) Methods for isolating and using a subset of cd8 t-cells that are resistant to cyclosporin
ES3041245T3 (en) Methods for detecting a mycobacterium tuberculosis infection
Levin et al. Availability of autoantigenic epitopes controls phenotype, severity, and penetrance in TCR Tg autoimmune gastritis
US20030013107A1 (en) Alpha 2 integrin: modulators of lymphocyte activation
CA3226437A1 (en) Antigen binding proteins specifically binding ct45
WO2011040978A2 (en) Immunodominant mhc dr52b restricted ny-eso-1 epitopes, mhc class ii monomers and multimers, and uses thereof
US20020146747A1 (en) TRAC1: modulators of lymphocyte activation
EISEN et al. VIII. Altered Peptide Ligands: Partial Agonists and Antagonists............... 4 1 IX. MHC Restriction by Self and Nonself MHC: The Paradox of Alloaggression. 43
US20050250113A1 (en) Mammalian magnesium/manganese sensing G protein coupled receptor